Clinical trial and regulatory efficiency get help from ctDNA, RWE at ASCO19

ASCO19 abstracts showcase the power of ctDNA and real-world data to add speed, relevance to trials.

This year’s crop of ASCO abstracts show companies are going full bore on pre- and post-market technologies that can speed up development and regulatory timelines.

In BioCentury’s analysis of 4,627 abstracts, over 500 feature circulating tumor DNA or real-world evidence, and they showcase how companies, institutions and regulatory agencies are applying the technologies.

The survey uses a machine learning-based analysis of abstracts published ahead of the American Society of Clinical Oncology meeting, for mentions of products, indications, targets, modalities or other hot topic terms (see “ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts”).

DNA shed from tumors into circulation carries information about the cancers’ mutations, and companies’ first use of the technologies has been in identifying

Read the full 1198 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE